DYNAVAX WKN: A12EV9 ISIN: US2681582019 Kürzel: DVAX Forum: Aktien Thema: Hauptdiskussion

https://www.stocktitan.net/news/DVAX/dynavax-reports-second-quarter-2025-financial-0d0z8edim68r.html

Genesis AI - kurz vor Ankündigung neuer Aufträge!!! Es gibt auch nur 6 million aktien im Umlauf. Mein Rat , beobachtet es 😏 …

https://investors.dynavax.com/news-releases/news-release-details/dynavax-reports-fourth-quarter-and-full-year-2024-financial

https://investors.dynavax.com/news-releases/news-release-details/dynavax-responds-deep-track-and-highlights-long-term-value

https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-200-million-share-repurchase-program

https://investors.dynavax.com/news-releases/news-release-details/dynavax-reports-third-quarter-2024-financial-results-and

https://www.prnewswire.com/news-releases/dynavax-reports-second-quarter-2024-financial-results-and-provides-business-updates-302215762.html

https://www.prnewswire.com/news-releases/dynavax-reports-first-quarter-2024-financial-results-and-provides-business-updates-302140240.html

Sehr ruhig hier.

https://www.prnewswire.com/news-releases/dynavax-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-full-year-2024-financial-guidance-302068488.html Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance

Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance https://www.prnewswire.com/news-releases/dynavax-reports-third-quarter-2023-financial-results-and-raises-full-year-revenue-guidance-301975340.html

Was passierte hier am kurs gestern und heute sieht es ähnlich aus?

Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance https://www.prnewswire.com/news-releases/dynavax-reports-second-quarter-2023-financial-results-and-raises-full-year-revenue-guidance-301892494.html • Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase • Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million • Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year

Ich hatte jetzt auch nichts anderes gefunden. Da war - vorhin jedenfalls - schon bissel Bewegung im 'Bio-Markt'. Das Volumen hier ist aber nicht besonders auffällig bisher.

Obwohl ich sehe gerade, dass generell die impfbuden heute zwischen 5 und 9 Prozent liegen... 🙄

@Summer.76, weißt du was wegen dem Anstieg heute? Good rumors vor der HV oder nur blinde Spekulation?